Market Forecast
Registering a CAGR of 5.4%, Anxiety Disorder Treatment Market is expected to reach USD 16.96 Million by 2025.
People with anxiety disorders may feel anxious most of the time or for the brief, intense episodes, which may occur for no apparent reason. The main categories of anxiety disorders include phobia, panic disorder, generalized anxiety disorder, social anxiety disorder, selective mutism, and separation anxiety disorder.
Numerous established players dominate the market. The key players are involved in strategic initiatives to strengthen their market positions and expand their geographic presence in developing regions. Many players are investing in research activities to develop effective therapies to sustain in the market. For instance, Eli Lilly and Company launched Duloxetine and Forest Laboratories, Inc. launched Vilazodone, used for the treatment of generalized anxiety disorder.
Market Influencers
Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major key players are positively influencing the market.
Regional Analysis
On a regional basis, the Americas is anticipated to dominate the global anxiety disorder treatment market owing to the rising incidence of anxiety disorders in the region. For instance, generalized anxiety disorder affects 6.8 million adults, or 3.1% of the US population every year. Moreover, rising awareness campaigns regarding the anxiety disorders by the government and public organizations is driving the growth of the market in this region. For instance, the Anxiety and Depression Association of America (ADAA) started an initiative named BreaktheStigma. This campaign raises awareness regarding mental illness and end stigma and creates hope for those affected by mental illness.
Europe is expected to hold the second-largest position in the global anxiety disorder treatment market owing to supportive government policies and raising public awareness about anxiety disorder treatments.
Asia-Pacific is anticipated to be the fastest-growing region is due to the growing prevalence of psychological conditions such as anxiety disorders, rising interest of major key players in emerging markets, good quality healthcare infrastructure in this region. The Middle East & Africa has the least share of the global anxiety disorder treatment market. This is attributable to limited healthcare infrastructure and a lack of awareness about anxiety disorder treatments in this region.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/anxiety-disorder-treatment-market-8455
Segmentation
The Global Anxiety Disorder Treatment Market has been segmented into drug class and end-user.
By drug class, the market has been segmented into SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants), pregabalin, buspirone, benzodiazepines, and others.
The global anxiety disorder treatment market, by end-user, has been segmented into hospitals, mental healthcare centers, asylums, and others.
Key Players
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Johnson & Johnson (US)
- AstraZeneca PLC (UK)
- Sanofi-Aventis (France)
- Forest Laboratories, Inc. (US)
- Pfizer, Inc. (US)
- GlaxoSmithKline PLC (UK)
- Lundbeck A/S (Denmark)
- Merck & Co., Inc. (US)
No comments:
Post a Comment